SCHEMBL2403473

SCHEMBL2403473

O=C(Nc1cccc(Br)c1)Oc1ccc2ncccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.62
NPC1 O15118 6/20 0.59
RAB9A P51151 5/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.51
POLB P06746 2/20 0.51
MAPT P10636 1/20 0.51
PABPC1 P11940 1/20 0.46
HSP90AA1 P07900 1/20 0.45
EGFR P00533 2/20 0.45
CDK8 P49336 2/20 0.45
ALOX15 P16050 2/20 0.43
HTT P42858 1/20 0.43
KDR P35968 1/20 0.42
TEK Q02763 1/20 0.42
NOTUM Q6P988 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28663512 0.86 ALDH1A1 (0.69) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL1568786 0.79 PABPC1 (0.65) ALDH1A1NPC1RAB9ACASP3SENP8
SCHEMBL6630687 0.76 HSP90AA1 (0.56) ALDH1A1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL5486894 0.75 NPC1 (0.67) ALDH1A1NPC1RAB9ACASP3SENP8
SCHEMBL11132897 0.75 KMT2A (0.82) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL2403448 0.75 KDM4E (0.72) ALDH1A1NPC1RAB9ACASP3SENP8
SCHEMBL19924516 0.74 ALDH1A1 (0.69) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL5267380 0.73 ALDH1A1 (0.68) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL2494747 0.72 ALDH1A1 (0.72) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL15252796 0.72 DGAT1 (0.60) ALDH1A1NPC1RAB9ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655801-B2 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-02 US claimed
EP-1831172-B1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2009-02-18 EP claimed
EP-1831172-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS Council of Scientific and Industrial Research (IN) 2007-09-12 EP claimed
WO-2006070394-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-06 WO claimed
US-20060142335-A1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2006-06-29 US claimed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2018-01-18 US disclosed
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO, INC. 2016-09-22 US disclosed
EP-2533645-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2016-07-27 EP disclosed
EP-2968220-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION Agenebio, Inc. (US) 2016-01-20 EP disclosed
WO-2014144801-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO INC. (US) 2014-09-18 WO disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
US-7655801-B2 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-02 US disclosed
EP-1831172-B1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2009-02-18 EP disclosed
EP-1831172-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS Council of Scientific and Industrial Research (IN) 2007-09-12 EP disclosed
WO-2006070394-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-06 WO disclosed
US-20060142335-A1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, BACE1, GRIN2A ALDH1A1 1226/4885NPC1 1345/4885RAB9A 227/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ALDH1A1 1226/4885NPC1 1345/4885RAB9A 227/4885
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885NPC1 544/4885RAB9A 187/4885
US-20060142335-A1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors ACHE, BCHE, NAAA ALDH1A1 885/4885NPC1 1934/4885RAB9A 935/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885NPC1 544/4885RAB9A 187/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885NPC1 544/4885RAB9A 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.